Tag Archives: (ABBV)

The Market Outlook for the Week Ahead, or Risk is Rising

On Saturday night, I received an urgent call from a Mad Hedge Concierge client who was expecting a stock market crash to ensue at any time. Would the US attack on Venezuela be the trigger? Not a chance, I answered. The military action would have no market impact. If anything, the removal of uncertainty in […]

January 5, 2026

Global Market Comments January 5, 2026 Fiat Lux 2026 Annual Asset Class Review A Global Vision FOR PAID SUBSCRIBERS ONLY Featured Trades: (SPY), (QQQ), (IWM), (AMZN), (AAPL), (GOOGL), (GS), (MS), (BAC), (C), (BLK), (ABBV), (BIIB), (AMGN), (TSLA), (DHI), (LEN), (PHM), (KBH), (TLT), (TBT), (JNK), (PHB), (HYG), (MUB), (LQD), (FXE), (EUO), (FXC), (FXA), (YCS), (FXY), (CYB), […]

Your Reminder That Markets Panic and Pipelines Don’t

AbbVie (ABBV) is back in the headlines, and for once, it’s not just the dividend crowd paying attention. The stock may have fumbled the market’s mood on Halloween with a 4% drop, but don’t let that spook you – what’s lurking underneath is far more intriguing than the reactionary selling would suggest. The company beat […]

The Laziness Premium

I spent last Tuesday afternoon on a call with a fund manager who runs $3 billion and couldn’t explain to me why his team was avoiding GSK (GSK). Something about HIV competition and patent cliffs and the usual hand-waving you get from analysts who haven’t actually dug into the numbers. I let him finish his […]